Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Provided By GlobeNewswire
Last update: May 14, 2024
PHILADELPHIA, May 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024 and provided recent business highlights.
Read more at globenewswire.com
